ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (SKU: B8300) is a potent, selective inhibitor of the transcription factor NRF2, with an IC₅₀ of 1.9 μM, enabling precise interrogation of NRF2-mediated antioxidant and detoxification pathways (APExBIO). ML385 demonstrates dose- and time-dependent suppression of NRF2 target gene expression in A549 NSCLC cell lines. In vivo, ML385 reduces tumor growth and metastasis in NSCLC mouse models, with increased efficacy in combination with carboplatin. The compound is insoluble in ethanol and water but dissolves at ≥13.33 mg/mL in DMSO. ML385 is widely used in research on cancer therapeutic resistance and oxidative stress modulation (Zhou et al., 2024).

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) is a master regulator of cellular defense against oxidative stress, modulating genes involved in antioxidant response, detoxification, and multidrug resistance (Zhou et al., 2024). Elevated NRF2 activity is implicated in cancer progression, particularly in non-small cell lung cancer (NSCLC), where it confers resistance to chemotherapeutic agents. Inhibition of NRF2 signaling can sensitize tumor cells to therapy by reducing antioxidant defenses and disrupting drug resistance mechanisms. Targeting NRF2 has also been shown to modulate ferroptosis, a form of regulated cell death linked to iron overload and oxidative injury. ML385 provides a selective tool for dissecting these pathways in preclinical models (APExBIO).

Mechanism of Action of ML385

ML385 is a small molecule that selectively inhibits NRF2 by binding to its Neh1 DNA-binding domain, preventing NRF2 from attaching to antioxidant response elements (ARE) in the promoter regions of target genes. This blockade results in decreased transcriptional activation of genes involved in redox homeostasis, detoxification, and multidrug resistance. In A549 NSCLC cells, ML385 induces dose- and time-dependent downregulation of canonical NRF2 targets such as NQO1, HO-1, and GCLC. The inhibition is specific: ML385 does not significantly affect related transcription factors or off-target signaling at effective concentrations (Zhou et al., 2024). In vivo, ML385 suppresses tumor growth by impairing NRF2-driven cytoprotection and enhancing susceptibility to oxidative stress and chemotherapeutic agents (APExBIO).

Evidence & Benchmarks

• ML385 exhibits an IC₅₀ of 1.9 μM for NRF2 inhibition in cell-based assays (APExBIO).
• In A549 NSCLC cell lines, ML385 suppresses NRF2-dependent gene expression in a dose- and time-dependent manner (Zhou et al., 2024, DOI).
• In NSCLC mouse models, daily intraperitoneal injection of ML385 (100 mg/kg) for six weeks reduces tumor growth and metastasis (Zhou et al., 2024, DOI).
• Combination therapy with ML385 and carboplatin leads to greater tumor suppression than either agent alone (APExBIO).
• ML385 enhances susceptibility to ferroptosis by downregulating NRF2-mediated antioxidant defenses (Zhou et al., 2024, DOI).

Applications, Limits & Misconceptions

ML385 is primarily used in preclinical cancer research to dissect the role of NRF2 in therapeutic resistance, antioxidant response regulation, and ferroptosis. It is especially valuable in NSCLC models, where NRF2-driven mechanisms underlie chemoresistance. The compound is also utilized to study oxidative stress modulation in liver injury and other disease models (Zhou et al., 2024).

Compared to earlier overexpression or knockdown models, small molecule inhibition with ML385 allows for temporal and dose-dependent control of NRF2 signaling (ML385: A Selective NRF2 Inhibitor for Cancer and Oxidativ...), extending prior reviews by detailing in vivo utility and combination regimens.

Recent reviews have highlighted ML385’s transformative role in overcoming therapeutic resistance (ML385: Transformative NRF2 Inhibitor for Advanced Cancer ...). This article updates these findings by synthesizing new evidence from liver disease models and ferroptosis studies.

For best practices in experimental design, see (Precision Targeting of the NRF2 Pathway: ML385 as a Catal...), which this article clarifies by providing specific dose and storage parameters for reproducibility.

Common Pitfalls or Misconceptions

• ML385 is not effective in models with NRF2-independent resistance mechanisms.
• The compound should not be stored in solution at room temperature for extended periods due to reduced stability.
• ML385 is insoluble in ethanol and water; improper solvent selection can cause precipitation and loss of activity.
• Off-target effects are minimal at recommended concentrations, but higher doses may affect unrelated pathways.
• ML385 is not a therapeutic drug and should not be used in human subjects.

Workflow Integration & Parameters

ML385 (CAS 846557-71-9) is supplied by APExBIO as a research reagent for in vitro and in vivo studies (product page). Recommended working concentrations in cell culture range from 1–10 μM. For in vivo mouse studies, typical dosing regimens involve 100 mg/kg/day administered intraperitoneally for up to six weeks (Zhou et al., 2024). The compound is insoluble in ethanol and water; dissolve in DMSO to ≥13.33 mg/mL for stock solutions. Store powder at -20°C and avoid long-term storage of solutions. Use freshly prepared solutions for maximal activity. ML385 enables time-resolved and dose-dependent inhibition of NRF2 for mechanistic studies, pathway validation, and combination therapy screening. Researchers should confirm NRF2-dependence of their model system before use.

Conclusion & Outlook

ML385 is a well-characterized, selective NRF2 inhibitor that has advanced research on cancer therapeutic resistance, oxidative stress, and ferroptosis. Its robust inhibition of NRF2 signaling in NSCLC and liver injury models enables precise mechanistic studies and the development of new combination therapies. For more details or to purchase, consult the ML385 product page at APExBIO. Ongoing research will further clarify its translational potential in diverse disease contexts.